Weight Loss; Metabolic Health; Type 2 Diabetes; Obesity; Insulin Sensitivity; Cardiovascular Support; Glucose Homeostasis; Research Compound; Combination Therapy

Product Purpose:

• • Significant Weight Loss: In phase 2 trials, Survodutide 4.8 mg achieved up to 18.7% body weight reduction at 46 weeks in adults with BMI ≥27 kg/m² without T2D, with 54.7% of participants losing ≥15% of body weight. A 10mg dose could potentially yield greater reductions, as weight loss did not plateau at 4.8 mg, suggesting further efficacy at higher doses.

  • Improved Glycemic Control: In T2D patients, Survodutide (up to 2.7 mg weekly or 1.8 mg twice weekly) reduced HbA1c by 1.5–1.7% after 16 weeks, comparable to semaglutide 1.0 mg. A 10mg dose may enhance glycemic control, particularly in longer-term studies.

  • Cardiometabolic Health Benefits: Survodutide reduced systolic blood pressure (SBP) by 8.6 mmHg and diastolic blood pressure (DBP) by 4.8 mmHg at 4.8 mg, and waist circumference by up to 12.1 cm, indicating potential cardiovascular risk reduction.

  • Liver Health Improvement: In MASH and cirrhosis patients, Survodutide reduced liver fat content, liver stiffness, and fibrosis biomarkers (e.g., Pro-C3, ELF score), suggesting therapeutic potential for MASH-related liver disease.

  • Enhanced Energy Expenditure: Glucagon receptor agonism increases fat oxidation and energy expenditure, complementing GLP-1’s appetite suppression for a dual approach to obesity management.

  • Tolerability in Cirrhosis: Survodutide’s pharmacokinetics remain consistent in patients with compensated or decompensated cirrhosis, supporting its use in MASH-related cirrhosis without dose adjustment

Research Use Only:

Suevodutide  is intended strictly for in vitro testing and laboratory experimentation. It’s not intended for human or animal medical use. It’s not a drug, food, or cosmetic and should not be misbranded, misused, or mislabeled as such.